Innovative Ab Drugs Development from target validation to IND application
Covering the whole process of antibody drug R&D from target validation to IND application
The platform is featured by a super-trillion phage display antibody library. Integrated with antibody engineering, in-vitro and in-vivo efficacy evaluation, production cell line construction, lab-scale production and other related- and supported-platforms. Covering the whole process of antibody drug R&D from target research to IND application.
Service Highlights
1.Complete integration capability
We integrated R&D platform for innovative antibody drug discovery is equipped with 10 functional modules and more than 40 technology platforms, covering the whole pre-clinical R&D process of antibody drug including pre-clinical candidate (PCC) confirmation, pre-clinical CMC development and IND application.
1.1. Confirmation of pre-clinical candidate (PCC) molecules
FM1 Raw material preparation
Ultra-fast recombinant protein customization
High-quality gram-amount antibody customization
Overexpression cell line for research purpose
FM2 Antibody generation
Super-trillion library size of innovative antibody drug discovery platform
FM3 In vitro efficacy screening
In vitro innovative drug efficacy evaluation
FM4 Antibody engineering
Deep antibody humanization
Ultimate antibody affinity maturation
FM5 Efficacy evaluation in animal models
Innovative drug efficacy screening in animal models
Pharmacokinetic analysis for antibody drugs
FM6 Quality analysis
Multi-dimensional antibody characterization analysis
1.2. Pre-clinical CMC Development
FM7 Cell line development
Cell line development for industrial production
FM8 Lab-scale process development
Antibody drug fermentation process R&D
Antibody drug purification process R&D
Antibody drug formulation process R&D
FM9 Quality control
Quality control
FM10 Pilot-scale production
Pilot-scale production
2. Powerful support from abundant platforms
2.1. Featured Platform I:Super-trillion library size of innovative antibody drug discovery platform
✔ Ten-trillion-level library capacity
✔ Thousands of lead molecules for initial screening
✔ Full coverage of molecule forms
✔ Multiple pathways for molecule generation
✔ Fit to challenging targets
✔ In-depth validation through nearly one hundred projects
✔ Matching with one-stop and high-throughput screening service
Trillion fully human antibody library
✔ Trillion library capacity
✔ Recombinant antibody library based on human B cell antibody gene
✔ Derived from nature with high druggability
✔ Median lead molecules: Over 300
Trillion fully human semi-synthetic antibody library
✔ Trillion library capacity
✔ Antibody library based on human B cell antibody gene rearrangement
✔ Derived from nature along with engineering design and high diversity
✔ Median lead molecules: Over 300
Trillion humanized 2C-type single domain antibody library
✔ 2-trillion library capacity
✔ The humanization degree based on framework is as high as 98%
✔ 2C-type single domain synthetic antibody library
✔ Median lead molecules: Over 600
Trillion humanized 4C-type trillion single domain antibody library
✔ 2-trillion library capacity
✔ The humanization degree based on framework is as high as 98%
✔ 4C-type single domain synthetic antibody library that is theoretically more stable and more degradation-resistant
✔ Median lead molecules: Over 600
Trillion fully human common light chain monoclonal antibody library
✔ Trillion library capacity
✔ Recombinant antibody library with a combination of selected light chains and diversified heavy chains
✔ Derived from fully human naive antibodies, with selected light chains and diversified heavy chains
✔ Median lead molecules: Over 300
Trillion cyclic polypeptide library
✔ Trillion library capacity
✔ A cyclic polypeptide library with fusion of selected tagged proteins and natural cyclic polypeptides
✔ Fit for the R&D of PDC, oral, and intracellular targets
✔ Median lead molecules (estimated): Over 100
Magnetic & Immunization & Tandem mouse antibody library
✔ Large library capacity and definite sequences costing months less compared with hybridoma method
✔ Diversified antigens, mouse, immunization method, and screening method
✔ Recombinant antibody library base on mouse B cell antibody genes after immunization
✔ Median lead molecules: Over 40
Magnetic & Immunization & Tandem alpaca antibody library
✔ Large library capacity and definite sequences
✔ Diversified antigens, mouse, immunization method, and screening method
✔ Single domain antibody obtained directly
✔ Median lead molecules: Over 30
2.2. Featured Platform II: Antibody engineering platform
Deep humanization at the level of over 95%
✔ 3D deep humanization design
✔ Distinctive database with reliable design
✔ Rich project experience and high success rate
✔ Eukaryotic expression system with natural modification
✔ Fast and qualified delivery within 4 to 6 weeks
Umate ltiaffinity maturation with up to a hundred times of improvement,
✔ Ultimate improvement of affinity activity
✔ Comprehensive verification of eukaryotic expression
✔ No limit on target types
✔ Rich project R&D experience
✔ Fast and qualified delivery within 6 weeks
2.3. Featured Platform III:Platform for efficacy evaluation in animal models
✔ Variety of mouse strains and disease models
✔ Standardized animal room and management system
✔ High-quality and customized one-stop service
✔ Rich project R&D experience
✔ Fast and qualified delivery within 56 days
2.4. Featured Platform IV: Platform for production cell line development
✔ High yield: Expression level of bispecific monoclonal antibody cell line in flask is up to 9.0 g/L
✔ Stable production: Over 60 PDL assessments are performed to support commercialized production.
✔ Premium quality: 11 assessment indicators are used to ensure expression production quality.
✔ Good compliance: cGMP standards are adopted and 4 sets of commercially authorized host cells are available.
✔ Ultra fast: It takes only 2.5 months to obtain monoclonal cell lines.
2.5. Featured Platform V:Platform for antibody fermentation process development
✔ Antibody yield up to 12 g/L
✔ Compliance with antibody quality standards
✔ Four sets of authorized host cells
Popular articles
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreAfter the base is put into operation, SMOC’s capability to provide genetically modified rat/mouse models and technical services including gene function research and drug development will be greatly enhanced.
Learn more